← boardnext 2028-01
CYDY
CytoDyn, Inc.distress 6/10 · elevated risk$0.200%today-46% from 52w high
Lead: Metastatic Colorectal Cancer (mCRC) · est. market ~$12B (approx, global)
Revenue
pre-revenue
Liquidity
$16M
Runway
0.7 yrs
Shares 1y
+8%
Price & events
-23.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.5%
1D
-9.5%
1W
-23.5%
1M
-33.7%
3M
-20.4%
6M
-31.4%
1Y
+42.1%
2Y
-88.1%
5Y
-96.7%
All
Overview
- Market Cap
- $271.84M
- Enterprise Value
- $296.72M
- Volume
- 110.81K
- 52 Week Range
- $0.20 – $0.37
- Total Shares
- 1.37B
- Float Shares
- 1.37B
- % Held by Insiders
- 0.01%
- % Held by Institutions
- 0.02%
- RVOL
- 0.06x
- Beta
- 1.16
Pipeline stages · 1 programs
350 mg leronlimab, 700 mg leronlimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-01 Estimated 50% readout ~2028-02-15 | Phase 2 | 350 mg leronlimab, 700 mg leronlimab | Metastatic Colorectal Cancer (mCRC) | — | active not recruiting |
Catalyst news & presentations · 3
- 2026-07-24earningsEarningsEarnings releaseyahoo
- April 2026conferencedata presentationsecondaryPhase 2leronlimab · AACR 2025 poster presenting early ctDNA readouts from CLOVER studySEC 8-K
- 2025-11-03partnershipEntered into Standby Equity Purchase Agreement with Yorkville for up to $30M.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — Metastatic Colorectal Cancer (mCRC)
- none identified
Recent news
- 2026-07-22CytoDyn settles class action with $500K cash an... - Pluang
- 2026-07-14Price to sales forward of CytoDyn Inc. – SWB:296 - TradingView
- 2026-07-08Price to earnings forward of CytoDyn Inc. – OTC:CYDY - TradingView
- 2026-06-11CytoDyn starts Phase 2a trial of leronlimab for early Alzheimer's with Weill Cornell Medicine - Pluang
- 2026-06-11CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer’s Disease - CytoDyn Inc.
- 2026-06-04Natera, CytoDyn Partner in Colorectal Cancer Study - Contract Pharma
- 2026-06-04Natera partners with CytoDyn on cancer treatment research - Investing.com
- 2026-06-04CytoDyn (CYDY) Teams Up with Natera for Cancer Research Collaboration - GuruFocus
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.